

Phase 1 clearance TCS → Phase 2 Tacrolimus +/- TCS → Phase 3 Maintenance with Tacrolimus

Calcineurin inhibitors retain skin barrier integrity

FDA U.S. Food and Drug Administration

Public Health Advisory: Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment
3/10/2005

The FDA is issuing a public health advisory to inform healthcare providers and patients about a potential cancer risk from use of Elidel (pimecrolimus) and Protopic (tacrolimus), products that are applied to the skin. This concern is based on information from animal studies.

In the meantime, this risk is uncertain and FDA advises that Elidel and Protopic should be used only as labeled, for patients who have failed treatment with other therapies.

Lymphoma among patients with atopic dermatitis

Medications	Cases: N = 2738	Controls N= 10949	OR
TCS low potency 1-2 yr	19	57	1.49
TCS low potency > 2 yr	8	30	1.16
TCS high potency 1-2 yrs	32	53	2.52
TCS High potency > 2 yr	17	22	3.21

Arellano JACI 2009 123; 1111-6
Hui R Ann Pharmacother 2009 Dec 43(12):1956-63

Antibiotics for Eczema treatment?

- Cochrane meta-analysis : No clear benefit
- Guidelines support use in impetiginised eczema

